Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Gilles Cottier
PharmaShots Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem
In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company's growth strategy. Shots: The acquisition of IsleChem has allowed the company to expand its manufacturing expertise in the US. Aceto currently has diversified access to a robust global supply chain network The acquisition…
May 11, 2021
Viewpoints_Dr. Med. Steven Hildemann
PharmaShots Interview: Ipsen’s Dr. Med. Steven Hildemann Shares Insight on the EC’s Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma
In an interview with PharmaShots, Prof. Dr. Med. Steven Hildemann, Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, and Patient Safety of Ipsen share his views on the approval of the combination regimen for aRCC. He also shed light on the company's near-term goals in the coming years. Shots: The EC approval is based…
May 11, 2021
Viewpoints_Thierry Abribat
PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism
In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer of Amolyt Pharma share his views on the clinical profile of AZP-3601. He also shed light on how it differs from other treatments in development for hypoparathyroidism. Shots: Amolyt Pharma presented positive data from the single ascending dose (SAD) portion of its Ph1 study evaluating AZP-3601…
May 10, 2021
Viewpoints_Sven Sjovall & Dr. Mark Watt
PharmaShots Interview: J&J’s Sven Sjovall & Dr. Mark Watt Share Insight on Nicorette’s Latest Digital Smoking Cessation Offering
In an interview with PharmaShots, Johnson & Johnson's Sven Sjovall, Sr Director, R&D Site Lead and Global Smoking Cessation, and Dr. Mark Watt, Senior Director Medical Affairs and Clinical Research at Johnson & Johnson share their views on Nicorette's latest digital smoking cessation offering and the science behind the QuickMist SmartTrack. They also shed some light on…
May 5, 2021
Viewpoints_Dr. Drew Falconer
PharmaShots Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic
In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson's and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in the US that allows patients to receive treatment from the doctor without leaving home. Shots: Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with their physicians,…
May 3, 2021
Viewpoints_Dr. Robert Koenekoop
PharmaShots Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a
In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University's Montreal Children's Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders? Shots: QR-421a demonstrated a concordant benefit in multiple measures of vision…
May 3, 2021
Viewpoints_Emmanuel Dulac
PharmaShots Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes
In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA's approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia.   Shots: The approval is based…
April 28, 2021
Viewpoints_Dr. Lara S. Sullivan and Dr. Ronald Herbst
PharmaShots Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio
In an interview with PharmaShots, Dr. Lara S. Sullivan, Chief Executive Officer, and Dr. Ronald Herbst, Chief Scientific Officer of Pyxis Oncology share insight on the importance of Series B funding and shed light on the company's strategy and near-term goals. Shots: Pyxis Oncology reported that it raised $152M in a series B on the heels of…
April 26, 2021
Viewpoints_Dr. Saoirse O'Sullivan
PharmaShots Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia
In an interview with PharmaShots, Dr. Saoirse O'Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS. Shots: The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health when affected…
April 23, 2021
Load more